

Interaction Report

Report ID:

Date Produced:

20 April 2025

Antiretroviral Treatment

Co-medications

Efavirenz (EFV)

Warfarin

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Efavirenz (EFV) + Warfarin

Coadministration has not been studied. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYP1A2 and 3A4. S-warfarin (more potent) is metabolized by CYP2C9. A case report and the analysis of warfarin maintenance dosage using data from 73 HIV-infected individuals showed that lower warfarin dosage was required for efavirenz compared to lopinavir/ritonavir or atazanavir/ritonavir based regimens. This observation is consistent with CYP2C9 inhibition by efavirenz leading to an increased warfarin activity. The international normalized ratio (INR) should be monitored.